NCT06740526View on ClinicalTrials.gov

Trial of the Impact of Sibeprenlimab on Immunoglobulin A Nephropathy Kidney Tissue

PHASE2RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

November 19, 2024

Primary Completion Date

April 17, 2029

Study Completion Date

April 17, 2029

Conditions
IgA Nephropathy
Interventions
DRUG

Sibeprenlimab

"Sibeprelimab SC (Period 1)~Sibeprelimab SC (Period 2)"

Trial Locations (5)

21144

RECRUITING

Clinical Research Site 369, Boston

57409

RECRUITING

Clinical Research Site 374, Dakota Dunes

77054

RECRUITING

Clinical Research Site 324, Houston

80230

RECRUITING

Clinical Research Site 330, Denver

M1H 3G4

RECRUITING

Clinical Research Site 305, Scarborough Village

All Listed Sponsors
lead

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY